Sofinnova Partners, acting on behalf of the Sofinnova Crossover I SLP fund, has declared to the AMF that on November 21 it exceeded the thresholds of 20% of the capital and voting rights in GenSight Biologics, and held 20.3% of the company's capital and voting rights.

This threshold crossing results from the subscription to a GenSight capital increase. The declaring party states that it has no plans to acquire shares, take control of the company or seek appointment to the Board.

Copyright (c) 2023 CercleFinance.com. All rights reserved.